ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.497,94
-0,09%
S&P 500
5.277,51
0,80%
Dow Jones
38.686,32
1,51%
Euro vs US Dollar
1,08484
-0,07%
Bitcoin
67.815,19
0,13%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. SciSparc Ltd (SPRC)

  7. SciSparc Ltd (SPRC) News

SPRC

SciSparc (SPRC)

SciSparc Ltd
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:SPRC
DatumZeitQuelleÜberschriftSymbolFirma
31/05/202413h17GlobeNewswire Inc.SciSparc Secures Strategic Advantage with Grant of European PatentNASDAQ:SPRCSciSparc Ltd
11/04/202414h15GlobeNewswire Inc.SciSparc to Acquire AutoMaxNASDAQ:SPRCSciSparc Ltd
21/03/202413h58GlobeNewswire Inc.SciSparc: MitoCareX Unveils Groundbreaking Discovery of Small Molecule Structure in Anti-Cancer ResearchNASDAQ:SPRCSciSparc Ltd
18/03/202412h29GlobeNewswire Inc.SciSparc Granted Another Patent, Strengthening its Core Technology in CanadaNASDAQ:SPRCSciSparc Ltd
14/03/202413h49GlobeNewswire Inc.SciSparc Achieves Major Milestone with First Patient Dosed in Autism Spectrum Disorder Clinical TrialNASDAQ:SPRCSciSparc Ltd
12/03/202413h14GlobeNewswire Inc.SciSparc: MitoCareX Reveals Promising Results with Discovery of Novel Anti-Cancer Small Molecule StructureNASDAQ:SPRCSciSparc Ltd
08/03/202415h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SPRCSciSparc Ltd
08/03/202413h11GlobeNewswire Inc.SciSparc Announces Enrollment of First Patient for its Clinical Trial for Children with Autism Spectrum DisorderNASDAQ:SPRCSciSparc Ltd
07/03/202413h49GlobeNewswire Inc.SciSparc Granted Patent for Core Technology in Multiple Jurisdictions in EuropeNASDAQ:SPRCSciSparc Ltd
07/03/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:SPRCSciSparc Ltd
06/03/202422h41GlobeNewswire Inc.SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management TechnologyNASDAQ:SPRCSciSparc Ltd
29/02/202415h07Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SPRCSciSparc Ltd
29/02/202414h35GlobeNewswire Inc.SciSparc Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of DosingNASDAQ:SPRCSciSparc Ltd
27/02/202422h15Edgar (US Regulatory)Form F-1 - Registration statement for certain foreign private issuersNASDAQ:SPRCSciSparc Ltd
27/02/202414h35Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SPRCSciSparc Ltd
27/02/202413h58GlobeNewswire Inc.SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine CompoundsNASDAQ:SPRCSciSparc Ltd
27/02/202413h58GlobeNewswire Inc.Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine CompoundsNASDAQ:SPRCSciSparc Ltd
20/02/202422h27Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SPRCSciSparc Ltd
20/02/202413h14GlobeNewswire Inc.Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based CompoundsNASDAQ:SPRCSciSparc Ltd
20/02/202413h14GlobeNewswire Inc.SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based CompoundsNASDAQ:SPRCSciSparc Ltd
12/02/202422h27Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SPRCSciSparc Ltd
29/01/202422h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SPRCSciSparc Ltd
29/01/202413h18GlobeNewswire Inc.SciSparc Announces Initiation of Patient Recruitment for its Clinical Trial with SCI-210 in Children with Autism Spectrum DisorderNASDAQ:SPRCSciSparc Ltd
25/01/202415h05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SPRCSciSparc Ltd
24/01/202413h42GlobeNewswire Inc.SciSparc Ltd. Announces $20 Million Standby Equity Purchase AgreementNASDAQ:SPRCSciSparc Ltd
22/01/202412h02Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SPRCSciSparc Ltd
19/01/202415h28GlobeNewswire Inc.SciSparc Advances the Acquisition Process of a Leading Vehicle Importer Company in Israel with the provision of a Bridge Loan of $1.4 millionNASDAQ:SPRCSciSparc Ltd
04/01/202413h18GlobeNewswire Inc.SciSparc and Clearmind Medicine Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic-Based TreatmentsNASDAQ:SPRCSciSparc Ltd
04/01/202413h18GlobeNewswire Inc.Clearmind Medicine and SciSparc Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic- Based TreatmentsNASDAQ:SPRCSciSparc Ltd
13/12/202314h18GlobeNewswire Inc.SciSparc Announces Positive Results for MitoCareX Bio with its Drug Discovery PlatformNASDAQ:SPRCSciSparc Ltd
 Showing the most relevant articles for your search:NASDAQ:SPRC

Kürzlich von Ihnen besucht

DBI
SDXP
SDAX
USOTC
DTEGY
Deutsche Telekom (QX)
COIN
BTCUSD
Bitcoin
TG
DTE
Deutsche Telekom
DBI
MDAX
MDAX
AMEX
SPY
SPDR S&P 500
PM
XAUUSD
Gold vs US Dollar
NYSE
MRK
Merck
USOTC
BNPQY
BNP Paribas (QX)
NYSE
XOM
Exxon Mobil
DBI
DAX
DAX
USOTC
RHHBY
Roche (QX)
USOTC
ADDYY
Adidas (QX)
TG
MBG
MercedesBenz
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten